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In observational studies, identification of associations within particular subgroups is the usual method of investigation. As an
exploratory method, it is the bread and butter of epidemiological research. Nearly everything that has been learned in epidemiology has
been derived from the analysis of subgroups. In a randomized clinical trial, the entire purpose is the comparison of the test subjects and
the controls, and when there is particular interest in the results of treatment in a certain section of trial participants, a subgroup analysis
is performed. These subgroups are examined to see if they are liable to a greater benefit or risk from treatment. Thus, analyzing patient
subsets is a natural part of the process of improving therapeutic knowledge through clinical trials. Nevertheless, the reliability of
subgroup analysis can often be poor because of problems of multiplicity and limitations in the numbers of patients studied. The naive
interpretation of the results of such examinations is a cause of great confusion in the therapeutic literature. We emphasize the need for
readers to be aware that inferences based on comparisons between subgroups in randomized clinical trials should be approached more
cautiously than those based on the main comparison. That is, subgroup analysis results derived from a sound clinical trial are not
necessarily valid; one must not jump to conclusions and accept the validity of subgroup analysis results without an appropriate judgment.
DESCRIPTORS: Randomized clinical trial. Subgroup analysis. Epidemiological methods. Interaction. Effect
modification.
Many scientific publications in-
clude, in addition to the main results,
a subgroup or subset analysis. In ob-
servational studies, identification of as-
sociations within particular subgroups
is the usual method of investigation,
with the data being presented by sex,
by age group, and so on. As an ex-
ploratory method, it is the bread and
butter of epidemiological research.
Nearly everything that has been
learned in epidemiology has been de-
rived from the analysis of subgroups.
In a randomized clinical trial
(RCT), the entire purpose is expressed
in the comparison of 2 subgroups—the
test subjects and the controls. And quite
commonly, when there is particular in-
terest in the results of treatment in a
certain section of trial participants (for
example, the women, the very young
or very old, or those with a specific
pattern of disease), a subgroup analy-
sis is performed. These subgroups are
examined to see if they are liable to a
greater benefit or risk from treatment.
Thus, analyses of subgroup data from
RCTs are undertaken to identify “effect
modifiers”, characteristics of the pa-
tients or treatment that modify the ef-
fect of the intervention under study.
Situations in which a particular
subgroup does not benefit at all from
treatment, or conversely, in which the
benefit is extremely large are certainly
important to discover. Unfortunately,
such situations in which the treatment
seems highly effective in one subgroup
and not at all in others happen quite
easily just by chance1. As shown by
Peto2, if patients are divided into 2 sub-
groups of similar size and if the treat-
ment is just significant overall (P <
0.05), there is a 1 in 3 chance that the
treatment effect will be large and sig-
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nificant in one of the subgroups and
negligible in the other. Thus, looking
at treatment effect in individual sub-
groups is a sure way to be misled by
the play of chance. This is particularly
true when, as is almost always the case,
there are several sensible ways to par-
tition the patients. Not surprisingly
then, the literature is fraught with con-
tradictory observations because the
subgroup that “clearly” benefits from
treatment varies at random3,4. Nonethe-
less, if we always insisted on focusing
all our attention on the overall results,
we would clearly not exploit the data
available to their full potential. Even if
we know that we would make fewer
mistakes, on average, by believing the
overall results and not the subgroup re-
sults, we still need to see the latter as
urgently as we need to see the former.
The results of subgroup analyses
have had major effects, sometimes
harmful, on treatment recommenda-
tions. For example, many patients with
suspected myocardial infarction who
could have benefited from thrombo-
lytic therapy may not have received
this treatment as a result of subgroup
analyses based on the duration of
symptoms before treatment and the
conclusion that streptokinase was only
effective in patients treated within 6
hours after the onset of pain5-7. A later,
larger trial showed that streptokinase
was effective up to 24 hours after the
onset of symptoms8. Conversely, in the
European Working Party on High
Blood Pressure trial, a reduction in car-
diovascular mortality was shown
among those using active treatment as
compared with those taking placebo9.
Further subgroup analysis went on to
demonstrate that no case could be
made for treatment in patients aged 80
and over.
Ideally, medical trials should yield
reliable and precise predictions of
clinical outcomes as a function of treat-
ment and patient characteristics. How-
ever, even among randomized studies,
conflicting reports exist of trials pur-
porting to evaluate the relative benefits
of the same treatments10,11. These in-
consistencies are often the result of in-
appropriate subset analysis conducted
in an effort to determine which treat-
ment is preferable for what kind of pa-
tient. Analyzing patient subsets is a
natural part of the process of improv-
ing therapeutic knowledge through
clinical trials. But the naive interpreta-
tion of the results of such examination
is a cause of great confusion in the
therapeutic literature. The adopted
study designs and methods of statisti-
cal analysis determine the extent to
which erroneous conclusions are likely
to result from the use of subset analy-
sis12-16.
The reliability of subgroup analy-
sis can often be poor due to problems
of multiplicity and limitations in num-
bers of patients studied17,18. First, exam-
ining the former condition, suppose
that 2 treatments have been randomly
assigned and subjects have been parti-
tioned into N mutually exclusive sub-
sets. For each subset we perform a sta-
tistical significance test with alpha set
at 0.05. Even if the treatments are iden-
tical, the probability of obtaining at
least one significant result for N = 10
is about 0.40 [Probability = 1-(1-
alpha)N]. That is, if the treatments are
equivalent for all 10 subsets, there is a
40% chance that at least one difference
will appear “significant” at the 0.05
level. For 5 subsets, the probability is
about 23%. For many clinical trials, the
number of subgroups that might be ex-
amined is far greater than 10. Moreo-
ver, very often authors will not report
how many subsets were exam-
ined12,19,20. Thus, the problem of per-
forming many comparisons is that it
may not be reasonable to interpret in-
dividual results at face value. In a sub-
group analysis, many tests are usually
performed, and the overall error prob-
ability is much higher than the nomi-
nal significance level of the test21,22. A
priori, the presence of important true
interactions is unknown, whereas the
spurious appearance of variability in
relative efficacy among many subsets
is almost a certainty.
Second, concerning the problems
with subgroup analysis caused by limi-
tations in numbers of patients enrolled
in the study, it is usual that constraints
of time and money restrict the sample
size of clinical trials to the minimum
number necessary to detect a difference
between the treated and the untreated
groups. As the total number of indi-
viduals studied in the experimental and
control groups is further partitioned in
subsets of particular interest, the num-
bers of study subjects in these sub-
groups become too small to support a
demonstration of statistical signifi-
cance. Hence, estimation of interac-
tions between treatment and patients’
characteristics is usually plagued by
insufficient statistical power.
For these reasons, subgroup analy-
ses are potentially misleading, and
there is a tendency to over emphasize
the results of such analyses. Therefore,
it is not surprising that it has been ar-
gued that treatment recommendations
based on subgroup analyses may do
more harm than good3,4,10,15,23-25. Differ-
ent classification schemes can generate
several different sets of subgroups, re-
sulting in numerous subset analyses in
the search for more specific differences
between treatments. Because of this
large amount of data, there is the dan-
ger that significance testing may be
used excessively, and the credibility of
subgroup analysis be poor, since, inevi-
tably, the chance of reporting some
false-positive finding increases26-29; this
is particularly true when the subgroup
categories were not clearly defined by
the original hypothesis. Thus, caution
must be exercised when evaluating the
results of subgroup analysis.
Although the best evidence for the
efficacy of medical interventions
comes from well-conducted, rando-
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mized controlled trials, unless such tri-
als are reported adequately, it is impos-
sible to assess that information. Results
of a RCT cannot be appropriately in-
terpreted without detailed information
about the methods used in the study.
Ideally, the report of such an evaluation
needs to convey to the reader informa-
tion concerning the design, conduct,
and analysis of the trial. This informa-
tion should provide the reader with the
ability to make informed judgments re-
garding the validity of the results re-
ported in the trial. However, such re-
ports frequently omit important fea-
tures of design and analysis19,30,31.
In response to increasing evidence
that reporting of RCTs is imperfect,
there has been a concerted effort to set
standards for reporting RCTs12,19,32,33.
These guidelines attempt to help au-
thors and editors improve the com-
pleteness of reporting RCTs. These
publications recommend important as-
pects to be mentioned for improving
the reporting of trials so editors can
provide authors with a list of features
to be used as a checklist for the report
of trials. The Standards of Reporting
Trials (SORT) group34 and the
Asilomar Working Group on Recom-
mendations for Reporting of Clinical
Trials in Biomedical Literature35 met to
produce a checklist of items that
should be included when reporting a
clinical trial, along with a suggestion
that editors add it to the Instruction for
Authors. This meeting resulted in the
Consolidated Standards of Reporting
Trials (CONSORT) statement (a check-
list of 21 items and a flow diagram)
that identifies key pieces of informa-
tion necessary to evaluate the validity
of a trial report36.
Even though the CONSORT state-
ment recommendations can lead to
more accurate and complete reporting
of the main comparisons between treat-
ment groups in RCTs, the quality of
reporting subgroup analysis of RCT
will not necessarily improve through
the use of these guidelines alone. That
is, these suggestions do not guarantee
that results from comparisons of treat-
ment responses in different categories
of patients are valid. While there have
been some reports on guidelines for
assessing the strength of inferences
based on subgroup analyses that can
assist clinicians in making decisions
regarding whether to base a treatment
decision on the results of such analy-
ses14,18,24,37, neither the CONSORT
statement nor the Instruction for Au-
thors in leading medical journals ad-
dress specific aspects of reporting sub-
group analyses in RCTs.
Recently, we reviewed the current
practice of reporting methodological
aspects of subgroup analysis in rando-
mized controlled clinical trials in 4
leading scientific journals38 and devel-
oped a list of important items to be in-
cluded in reports of subgroup analysis
of RCTs (Table 1). Our data show that
inaccurate and incomplete reports oc-
cur frequently. When authors fail to
mention essential features of the design
and methods used in a subgroup analy-
sis, they are omitting much needed in-
formation for the readers to assess the
validity of the results presented. At the
same time, readers need to be more
aware of the important distinctions be-
tween inferences based on the main
comparison of a RCT, and those based
on results of subgroup analyses. In ad-
dition to information on the design and
methods of the trial, specific aspects
pertaining the conduct of the subset
analysis must be reported in order to
make informed judgments on the
strength of inferences drawn from such
analyses of RCTs.
CONCLUSIONS
Current practices of reporting sub-
group analysis of RCTs are far from
ideal. Incomplete and inaccurate reports
are the norm, rather than the exception.
This incomplete and inaccurate report-
ing imposes severe limitations on the
correct interpretation of the results; it
almost always precludes correct inter-
pretation. We emphasize the need for
readers to be aware that inferences
based on comparisons between sub-
groups in RCTs should be approached
more cautiously than those based on the
main comparison. That is, subgroup
analysis results derived from a sound
clinical trial are not necessarily valid.
Unless specific methodologic aspects of
the subgroup analysis are explicitly
mentioned, accurate evaluation by the
reader is not possible. One must not
jump to conclusions and accept the va-
lidity of subgroup analysis results with-
out an appropriate judgment.
Table 1 - List of important methodological items in reporting subgroup analysis
in randomized clinical trials.
1. A priori/post-hoc subgroup analysis (information on whether the subgroup analysis
preceded or followed the analysis);
2. Number of subgroups examined (information about how many subgroups were examined);
3. Justification for subset definition (information explaining how the subgroups were
stratified);
4. When subgroups were delineated (information on whether the subgroups were defined after
or before randomization);
5. Statistical methods (the names of specifics tests or techniques used for statistical analyses);
6. Power (information describing the determination of sample size or the size of detectable
differences);
7. Clinical significance (information on the clinical significance of the interaction); and
8. Overall treatment comparison (information about the significance of the comparison
between the main treatment groups).
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We need to enforce recommenda-
tions and guidelines for reporting re-
sults of subgroup analysis in clinical
trials. This enforcement would improve
the quality of published trials, helping
clinicians make more informed deci-
sions about the best treatment choices.
As readers find these methodological
features repeatedly mentioned in
RCTs, they will become more aware of
the relevance of these items for the in-
terpretation of the results, improving
their assessment of the validity of the
study findings. In addition, more struc-
tured reports will help editors and re-
viewers in their deliberations regarding
submitted manuscripts.
The decision of whether to base
clinical practice on the average esti-
mate of effect from the overall analy-
sis or on a subgroup analysis depends
on the careful assessment of the crite-
ria described throughout this text. It
might be tempting to take one extreme
or the other: to base decisions either on
the overall estimate of effect or on the
most applicable subgroup analysis.
However a thoughtful approach is
more likely to result in the most ben-
efit and the least harm for patients. It
is essential that this information is
completely and accurately reported in
clinical trials. A better report of meth-
ods of subgroup analysis will ulti-
mately benefit patients, since more
comprehensive and complete reports
are more likely to lead clinicians to
make correct therapeutical decisions.
We acknowledge that applying
these standards for reporting subgroup
analysis presents intrinsic difficulties
and challenges. The list of recommen-
dations for reporting subgroup analy-
sis of clinical trials that we developed
will be modified and improved as it is
disseminated and made available to
wider audiences. We invite all inter-
ested editors and readers to join us in
using and improving this checklist.
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Em estudos de observação, a iden-
tificação de associações dentro de
subgrupos particulares é o método ha-
bitual de investigação. Como um mé-
todo exploratório, faz parte do dia-a-
dia da pesquisa epidemiológica. Qua-
se tudo o que se sabe hoje em Epide-
miologia foi derivado da análise de
subgrupo. Em ensaios clínicos rando-
mizados, o propósito principal é a
comparação dos indivíduos sob expe-
rimentação e os controles, e quando
nós estamos particularmente interessa-
dos nos resultados do tratamento em
uma certa seção de participantes do
ensaio, uma análise de subgrupo é exe-
cutada. Estes subgrupos são examina-
dos para verificar se eles foram objeto
de um maior benefício ou malefício
secundário ao tratamento. Assim, ana-
lisar subconjuntos de pacientes é uma
parte natural do processo de melhorar
o conhecimento terapêutico através de
ensaios clínicos randomizados. Não
obstante, a confiança na análise de
subgrupo pode ser pobre devido a pro-
blemas de multiplicidade de compara-
ções e limitações em números de pa-
cientes estudados. A interpretação
simplista dos resultados de tal técnica
é uma causa de grande confusão na li-
teratura terapêutica. Nós enfatizamos a
necessidade de chamar a atenção dos
leitores que as conclusões baseadas em
comparações entre subgrupos em en-
saios clínicos randomizados sejam exa-
minadas com mais cautela do que
aquelas baseadas na comparação prin-
cipal. Ou seja, resultados de análise de
subgrupo provenientes de ensaios clí-
nicos corretamente desenhados não são
necessariamente válidos, portanto, não
devemos tirar conclusões precipitadas
e aceitar a validade dos resultados sem
um julgamento judicioso.
DESCRITORES: Ensaio clínico
randomizado. Análise de subgrupo.
Métodos epidemiológicos. Interação.
Modificação de efeito.
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